LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, ...
EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...
A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...
Chronic sleep deprivation acts as a systemic stressor, elevating risks for cardiovascular disease and metabolic dysregulation while impairing cognitive function.
Menopause represents a profound systemic shift involving cardiovascular, skeletal, and neurological health, requiring tailored clinical intervention.
2025, A Year of Momentum: Advancing Toward a Potential Breakthrough in Ovarian Cancer Treatment ...
Aldeyra ’s Reproxalap is the core catalyst. The FDA will make its decision on this asset by March 16, 2026, after a ...
The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or ...
As 2026 approaches, global debt levels remain historically elevated. Years of crisis response, from the Global Financial ...
Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.
Morning Overview on MSN
Tumors disappeared with this new drug, minus the scary toxicity
For decades, cancer patients have been told that shrinking tumors meant accepting brutal side effects as the price of ...
Despite the definitive failure of Novo Nordisk’s semaglutide in Alzheimer’s, biotech executives, analysts and other industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback